New ESMO Tumor DNA Scale Helps Match Patients to Optimal Targeted Treatments

August 22, 2018 – A new scale for tumor DNA mutations called ESCAT (European Society for Medical Oncology [ESMO] Scale for Clinical Actionability of Molecular Targets) is aiming to simplify and standardize choices for targeted cancer treatment. Information about the development and use of the scale in practice was published by Mateo et al in Annals of Oncology. The goal of the use of ESCAT is to optimize patient care by making it easier to identify patients with cancer … (leggi tutto)